Histone Deacetylase Inhibitors (HDAC inhibitors) represent a rapidly evolving segment within the pharmaceutical and biotechnology industries. These compounds have gained significant attention for their potential in the treatment of various diseases, particularly cancer. The HDAC inhibitors market encompasses a broad range of applications, from oncology to neurology, and is characterized by ongoing research and development efforts, clinical trials, and strategic collaborations.
